Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Pearson

Showing results (151-160 of 169) with videos related to

Pageof 17
Sort By:
Nature|September 15, 2015
Transcriptional plasticity promotes primary and acquired resistance to BET inhibitionPhilipp Rathert, Mareike Roth, Tobias Neumann, et al.
Plos One|July 14, 2022
Interrogating intervention delivery and participants' emotional states to improve engagement and implementation: A realist informed multiple case study evaluation of EngagerLauren Weston, Sarah Rybczynska-Bunt, Cath Quinn, et al.
International Journal of Chronic Obstructive Pulmonary Disease|March 18, 2026
Non-Pharmacological Breathlessness Action Plans for People with COPD and Their Support People: A Scoping Review and Survey of Current PracticeTim Luckett, Mary M Roberts, Muneeba Tariq Chaudhry, et al.
Journal of Medicinal Chemistry|February 26, 2016
Structure-Based Design of an in Vivo Active Selective BRD9 InhibitorLaetitia J Martin, Manfred Koegl, Gerd Bader, et al.
Chemmedchem|December 4, 2020
Getting a Grip on the Undrugged: Targeting β-Catenin with Fragment-Based MethodsDirk Kessler, Moriz Mayer, Stephan K Zahn, et al.
Biorxiv : the Preprint Server for Biology|February 7, 2023
Combined KRAS<sup>G12C</sup> and SOS1 inhibition enhances and extends the anti-tumor response in KRAS<sup>G12C</sup>-driven cancers by addressing intrinsic and acquired resistanceVenu Thatikonda, Hengyu Lu, Sabine Jurado, et al.
Thrombosis Research|January 18, 2026
Developing a decision support tool for the continuation or deprescribing of antithrombotic therapy in patients receiving end-of-life care: Results of a European Delphi study, Isabelle Mahé, Skerdi Haviari, et al.
The British Journal of Psychiatry : the Journal of Mental Science|August 17, 2022
Evaluation of a complex intervention for prisoners with common mental health problems, near to and after release: the Engager randomised controlled trialRichard Byng, Tim Kirkpatrick, Charlotte Lennox, et al.
Mabs|December 9, 2024
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancerPeter Jung, Stefan P Glaser, Jing Han, et al.
Cancer Discovery|August 21, 2020
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK InhibitionMarco H Hofmann, Michael Gmachl, Juergen Ramharter, et al.
Pageof 17

Showing results (151-160 of 169) with videos related to

Sort By:
Pageof 17
Nature|September 15, 2015
Transcriptional plasticity promotes primary and acquired resistance to BET inhibitionPhilipp Rathert, Mareike Roth, Tobias Neumann, et al.
Plos One|July 14, 2022
Interrogating intervention delivery and participants' emotional states to improve engagement and implementation: A realist informed multiple case study evaluation of EngagerLauren Weston, Sarah Rybczynska-Bunt, Cath Quinn, et al.
International Journal of Chronic Obstructive Pulmonary Disease|March 18, 2026
Non-Pharmacological Breathlessness Action Plans for People with COPD and Their Support People: A Scoping Review and Survey of Current PracticeTim Luckett, Mary M Roberts, Muneeba Tariq Chaudhry, et al.
Journal of Medicinal Chemistry|February 26, 2016
Structure-Based Design of an in Vivo Active Selective BRD9 InhibitorLaetitia J Martin, Manfred Koegl, Gerd Bader, et al.
Chemmedchem|December 4, 2020
Getting a Grip on the Undrugged: Targeting β-Catenin with Fragment-Based MethodsDirk Kessler, Moriz Mayer, Stephan K Zahn, et al.
Biorxiv : the Preprint Server for Biology|February 7, 2023
Combined KRAS<sup>G12C</sup> and SOS1 inhibition enhances and extends the anti-tumor response in KRAS<sup>G12C</sup>-driven cancers by addressing intrinsic and acquired resistanceVenu Thatikonda, Hengyu Lu, Sabine Jurado, et al.
Thrombosis Research|January 18, 2026
Developing a decision support tool for the continuation or deprescribing of antithrombotic therapy in patients receiving end-of-life care: Results of a European Delphi study, Isabelle Mahé, Skerdi Haviari, et al.
The British Journal of Psychiatry : the Journal of Mental Science|August 17, 2022
Evaluation of a complex intervention for prisoners with common mental health problems, near to and after release: the Engager randomised controlled trialRichard Byng, Tim Kirkpatrick, Charlotte Lennox, et al.
Mabs|December 9, 2024
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancerPeter Jung, Stefan P Glaser, Jing Han, et al.
Cancer Discovery|August 21, 2020
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK InhibitionMarco H Hofmann, Michael Gmachl, Juergen Ramharter, et al.
Pageof 17